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Background. Studies using clinical measures to track AD progression often assume linear declines over the entire 
course of the disease, which may not be justified. The objective of this study was to model change in measures of the 
clinical severity of Alzheimer's disease (AD) over time. 
Methods. We developed a method to apply growth curve models to prospective data and characterize AD Patients' 
functional change over time. Data from the modified Mini-Mental State Examination (mMMSE) and measures of basic 
and instrumental ADL, administered semiannually for up to 5 years to 236 patients with probable AD, were modeled. 
Results. The rate of decline in mMMS scores per 6-month interval gradually increased as scores dropped from the 
maximum of 57 to 20. The rate of decline then decreased as scores approached 0, resulting in an inverse' 'S'' curve. The 
rate of increase in instrumental ADL scores per interval attenuated as the scores increased, while that for basic AOL 
scores across intervals was constant. 
Conclusions. Differences in the pattern of progression of the three measures is in part a function of their psychometric 
properties. The progression curves may also reflect content-specific features of the instruments. Superimposition of the 
modeled decline in these three content areas suggests· a hypothetical model of the relative timing of cognitive and 
functional changes in AD. 
THE Predictors Study was designed to develop models for predicting the course of an individual patient's Alzhei-
mer's disease (AD) (1), Much ofour effort has been devoted 
to examining the predictive utility of specific clinical vari-
ables such as extrapyramidal signs (2), psychosis (2), and 
age at onset (3) in an attempt to explain heterogeneity in 
disease course. 
Important for prediction is an adequate description of the 
natural history of AD. The standard approach is to quantify 
disease progression by administering global measures of 
cognitive or functional disease severity at regular intervals 
over the course of the disease. The Mini-Mental State 
Examination (MMSE) (4), which assesses cognition, and 
the Blessed Dementia Rating Scale (BDRS) (5), which 
assesses instrumental and basic activities of daily living, are 
commonly used for this purpose, and several studies have 
estimated expected rates of change (6-9). Decline on these 
scales has been viewed as linear, with constant change 
expected over any particular time interval. However, this is 
not the case. Annual change in MMSE scores for partici-
pants in CERAD (the consortium to establish a registry for 
Alzheimer's disease) differed as a function of the score 
itself; more marked change occurred in the moderate range 
of scores (I 0). This observation was simply based on inspec-
tion of annual changes associated with each score and was 
not based on any formal model of the decline process. A 
"trilinear model" of decline has been proposed, in which 
rapid change occurs in the midrange of disease severity with 
relative plateaus early and late in the disease (11). However, 
there is no basis for assuming that this model of decline 
applies equally to all measures of disease severity. 
The observed pattern of decline in scores may also be a 
function of the psychometric properties of each scale. Thus, 
they may not actually reflect differences in the rate of 
progression of the disease itself. For example, some tests 
tend to be less sensitive to changes at their scoring extremes 
than in their midrange. These ceiling and floor effects can 
influence observed rates of change, yet the disease continues 
to progress once a patient has reached minimum scores. 
Also, both the MMSE and BDRS are made up of heteroge-
neous items that reflect different cognitive abilities or func-
tional activities, and these domains are unequally repre-
sented. Patterns of progression in a test score may therefore 
be a function both of the relative weight of the component 
items and of potential differences in the point of the disease 
at which specific domains are affected. 
We developed a method to extend nonlinear growth curve 
models (12) to characterize changes in prospectively collected 
data ( 13). This modeling approach is flexible in that it allows 
changes in the "shape" of the curve in order to best fit the 
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data. In addition, this approach allows the incorporation of 
subgroups or tin1e-dependent covariates. In the explication 
of the statistical procedures, we applied them the progres-
sion of modified Mini-Mental State (mMMS) scores in AD, 
and also evaluated differences in the pattern of mMMS score 
changes in patients with young and old age at onset. We now 
use this modeling approach to compare disease progression 
as measured by the mMMS and assessments of instrumental 
and basic activities of daily living. 
METHODS 
Subjects 
All subjects were participants in the Predictors Study, a 
multi-site, longitudinal study of disease course in AD. Two 
hundred thirty-six patients with probable Alzheimer's dis-
ease were recruited into the study at three sites: Columbia-
Presbyterian Medical Center, New York; Johns Hopkins 
Hospital, Baltimore; and Massachusetts General Hospital, 
Boston. Details of inclusion and exclusion criteria, and 
recruitment methods have been previously described (!). 
Briefly, all patients were required to meet NINCDS-
ADRDA criteria (14) for probable Alzheimer's disease 
(pAD). To ensure that severity of dementia was mild at study 
entry, all patients were required to have an mMMS score of 
30 or above (corresponding to approximately 16 on the 
standard MMSE). Patients witr small subcortical lesions 
that were clinically and historically silent were included. 
However, patients with cortical lesions of any size or loca-
tion, or with focal cortical atrophy in a specific vascular 
distribution were excluded. 
Procedures 
All patients were seen at 6-month intervals and underwent 
the following evaluations. 
Cognitive asses.nnent. - Cognitive function was exam-
ined using the modified Mini-Mental State Examination 
(15). This instrument includes all items from the standard 
Mini-Mental State Examination (4) and also includes the 
Wechsler Adult Intelligence Scale Digit Span subtest (16), 
and additional attention/calculation, general knowledge, 
language, and construction items. The maximum score on 
this test is 57. This is a valid and reliable instrument (17) that 
is brief yet informative. 
Functional assessment. - Functional capacity was rated 
using the BDRS (Part 1) (5) using a structured interview to 
guide and standardize BDRS administration. A previous 
factor analysis of the BDRS items in 187 patients with pAD 
demonstrated four factors, and prospective data from a 
separate cohort of 67 patients suggested that the factors' 
pattern of progression differs (18). In the current analyses, 
we concentrated on two factors which reflect two specific 
types of ADL measured by the BDRS. 
Instrumental ADL (IADL) was assessed by items 1-7, 
which address functions such as orientation, performing 
chores, and remembering lists. These items are traditionally 
scored on a 3-point scale as absent (score = 0), partially 
(0.5), or fully impaired (1). To simplify analysis, this 3-
point scale was recoded, and ranged from 0 to 2. Thus, the 
maximum score for IADL was 14. Basic ADL (BADL) was 
measured by 3 items: eating, dressing, and toileting. These 
are rated on a 4-point scale ranging from 0 to 3. Thus, the 
1naxilnum BADL score was 9. For both ADL domains, a 
higher score denotes more itnpairment. 
Statistical Analysis 
The mathematical properties of the modeling approach 
have been described (13). This approach applies the princi-
ples of growth models, which can be specified by an equa-
tion that assumes that the growth rate, or change in a test 
score, is a function of the present score. The modeling 
procedure begins by calculating changes in test scores be-
tween all adjacent 6-month visits for each subject. Thus, 
only patients with at least two consecutive scores on a 
measure can be included in the calculations. The goal is to 
characterize the conditional average change in a score based 
on the current score; E(Yk+t-YklYk), where Yk represents a 
test score at time k, Yk+i-Yk is the change in the next 
interval, and E denotes the expectation operation. We model 
the conditional average change with a function in a form 
similar to Von Bertanalffy's growth curve model (12), 
which unifies n1onomolecular, logistic, Gompertz, and other 
models. The values of the tnodel paran1eters determine the 
"shape" of the model and the point of maximal change in 
scores (if one exists). A quasi-likelihood approach is used to 
estimate tnodel parameters to best fit the data. The procedure 
n1inimizes the mean square error of prediction of changes in 
test scores; 95% confidence intervals can be calculated for 
the various tnodel parameters as well. 
We applied the model in two complementary ways. First, 
we used the model to predict change in a score from one visit 
to the next as a function of the current score. Second, we 
simulated the progression of test scores over time, given a 
specific starting score. In this case, the starting score gener-
ates a prediction of the score at the next time interval, and 
this process is repeated until the score reaches its upper or 
lower bound. The generated curve is therefore a generalized 
representation of the progression of the test score over time. 
The modeling procedure was applied separately to the 
mMMS total score and the two BDRS factors. 
RESULTS 
De1nographics 
Mean patient age at intake into the study was 73.1 (SD 
±8.9) yrs. There were 96 men and 140 women, and mean 
years of education was 13.10 ( ± 3.66). At the initial vis-
it, mean estimated duration of illness was 3.9 (±2.4) 
yrs; mMMS, 37.9 (±5.6) (by design, no patient's mMMS 
score was below 30); IADL, 6.01 (±2.6); and BADL, 
0.52 ( ±0.91). 
mMMS Progression 
Two hundred eighteen subjects completed the mMMS at 
two or n1ore consecutive visits and were followed for 6 to 54 
months. Observed scores ranged from 0 to 57. The change 
between two consecutive visits ranged from a decline of 29 
points to an 8-point improvement. We applied a basic 
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growth model to the mMMS scores. The derived growth 
curve function was as follows: 
E(Y,.,-Y,) IY, ~ -. !SY,* ln(57/Y,) O~Y,<57 
Substituting a current mMMS score for Y kin the equation 
generates a prediction of the amount of decline in the score 
over the subsequent 6-month interval. The standard devia-
tion of this estimate is 4.88. The value -.18, which is 13 in 
the formally described modeling procedure (13), is an esti-
mated value that, in effect, determines the dynamic change 
in scores. The standard errorof the estimate of 13 is .OJ. The 
mMMS score at which change was maximal was 19 (95% 
CI: 13-26). Ninety-five percent of the residual scores (pre-
dicted minus observed change) were within 2 standard devia-
tions of 0 and there was no specific pattern to the residual/ 
score plot, indicating that the model fits the data well. 
For each given score, we calculated the associated condi-
tional average change over a 6-month period. For purposes 
of comparison, we also calculated the mean of the empiri-
cally observed changes for each mMMS score. Figure I 
demonstrates that the smooth curve generated from the 
model's prediction fits the empirically observed average 
changes. The observed average changes across 6-month 
intervals fluctuate markedly for low and high scores because 
there were few observations available in these score ranges. 
It is apparent from Figure I that the decline in mMMS scores 
over a 6-month period gradually increases as scores drop 
from 57 to 19; the rate of decline then decreases as the score 
approaches 0. 
We also used the model to generate a curve representing 
the decline in mMMS scores for a patient with an initial 
mMMS value of 56 (Figure 2). This curve again demon-
strates that the most rapid decline in mMMS scores is in the 
midrange of the disease, with less rapid decline in scores 
early and late in the disease. From the curve we may roughly 
estimate that the total period of decline in mMMS scores is 
about 15 years. 
Instrumental ADL 
Two hundred twenty-one subjects completed the BDRS at 
two or more consecutive visits and were followed for 6 to 54 
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Figure 1. Based on the growth curve model, predicted average change 
of mMMS scores over a 6-month interval as a function of the current 
score. The average of empirically observed score changes is presented for 
comparison. 
months. Observed scores ranged from 0 to 14. The change 
between two consecutive visits ranged from -7 to 8. We 
applied a growth model to the instrumental ADL scores. The 
derived function was as follows: 
E(Y..,-Y,) IY, ~ .145(14-Y,) 
Substituting a current instrumental ADL score for Y k in 
the equation generates a prediction of the amount of increase 
in the score over the subsequent 6-month interval. The 
standard deviation of this estimate is I. 95. In this case, 13 ~ 
.145 with a standard error of .01. Ninety-five percent of the 
residual scores (predicted minus observed change) were 
within 2 standard deviations of 0 and there was no specific 
pattern to the residual/score plot, indicating that the model fit 
the data well. 
Figure 3 displays the predicted conditional average 
change over a 6-month period for each given score, as well 
as the mean of the empirically observed changes. The 
smooth curve generated from the model fits the empirically 
observed (actual) changes. 
Taking an initial IADL value of I, we used the model to 
generate a curve for increase in IADL scores (Figure 4). 
From the curve we may roughly estimate the period of 
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Figure 2. A time series of mMMS scores generated by the growth curve 
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Figure 3. Based on the growth curve model, predicted average change of 
instrumental ADL scores over a 6-month interval as a function of the current 
score. The average of e1npirically observed score changes is presented for 
comparison. 
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Figure 4. A time series of instrumental ADL scores generated by the 
growth curve model with the initial score of I. 
BasicADL 
Observed BADL scores ranged from 0 to 9. Note that 0 
denotes no impairment and 9 denotes maximal impairment. 
The change between two consecutive visits ranged from -3 
to 9. We applied a growth model to the basic self-care 
scores. The derived growth curve function was as follows: 
E(Y,.,-Y,)IYk = .46 O~Y,<9 
There is no difference in the amount a score changes per 6-
month interval as a function of the current score; in each case 
the score increases .46 points. The standard deviation of this 
estimate is 1.28. Of course, once the score reaches 9 it no 
longer increases. In this case f3 = .46 with a standard error 
of .043. Ninety-five percent of the residual scores (predicted 
minus observed change) were within 2 standard deviations 
of 0, and there was no specific pattern to the residual/score 
plot, indicating that the model fit the data weU. 
Figure 5 displays the predicted associated conditional 
average change over a 6-month period for each given score, 
as weU as the mean of the empiricaUy observed changes. 
Taking an initial basic self-care score of 0, we used the 
model to generate a curve for increase in scores (Figure 6). 
From the curve we may roughly estimate the period of 
decline in BADL scores as about 10 years. 
DISCUSSION 
We used a growth curve modeling procedure to examine 
the progression of three different measures of the severity of 
AD. The pattern of change in scores over time differed 
across the three measures. For the mMMS there was a period 
of rapid decline in scores with markedly slower progression 
early and late in disease course. The slow progression early 
in the disease may occur because the earliest cognitive 
changes of AD might not be detectable by the mMMS. If this 
were the case, more sensitive or challenging tests might 
show more rapid decline even early in the disease. Alter-
nately, the earliest changes in the mMMS may be occurring 
before the clinical signs of AD have emerged and may truly 
indicate relatively slower progression in the earliest portions 
of the disease process. Late in the disease, the rate of change 
in the mMMS score again slows, and the score plateaus close 
to its minimum score. One possible explanation for this is 
that cognitive decline is still occun·ing, but cannot be de-
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Figure 5. Based on the growth curve model, predicted average change 
of basic AOL scores over a 6-month interval as a function of the current 
score. The average of empirically observed score changes is presented for 
comparison. 
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Figure 6. A time series of basic ADL scores generated by the growth 
curve model with the initial score of l. 
tected by the mMMS items, since at this point patients are 
not capable of performing accurately on most of them. To 
this end, some investigators have proposed alternate mental 
status tests for severely ilnpaired patients, in order to capture 
additional information about cognitive status after the 
mMMS scores reach bottoll) (19-21). We do not feel that 
this is the case with the mMMS, because many patients 
continued to answer a few mMMS questions correctly even 
during this second plateau period. It would be of value to 
apply the growth curve modeling technique to data from a 
"severe impairment" battery in order to determine whether 
there is further progression of cognitive impairment that the 
mMMS cannot detect or whether a true endpoint of depleted 
cognitive capacity has been reached. 
The BORS measures lADL and BADL as different do-
mains (18) and, as we demonstrate, these two aspects of 
ADL progress at different rates and in different patterns. 
Difficulties with !ADL increase more rapidly earlier in the 
disease, while BADL difficulties have a slow, linear in-
crease. One practical implication of these findings is that 
prospective analyses cannot assume that different measures 
of AD severity are interchangeable; there are differences in 
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how measures change over time. There are probably several 
reasons for these differences in progression including the 
psychometric properties of the measures as discussed above. 
lt is intriguing to speculate that our results also reflect some 
differences in the neuroanatomic substrate for the measured 
deficits, but there is no direct support for this idea from the 
present data. 
The formulas derived for each model may be used to 
calculate a rough estimate of the amount of time it wi11 take 
for a patient to move from one score to another. However, 
the modeling procedure does not provide techniques for 
calculating confidence intervals for individual estimates. 
The procedure is simply to enter the starting score into the 
appropriate formula. This yields the estimated change in the 
score over a 6-month period. This process can be repeated 
until the target score is reached. Figures 2, 4, and 6 can be 
used as rough guides for this estimation. 
While some studies have treated prospective decline in 
scales that assess AD as linear, the present study and several 
others (10, 11) emphasize the need for alternate approaches 
to modeling AD progression. Brooks et al. (11) have sug-
gested a trilinear model for decline in AD. This model posits 
three periods in the course of AD, a period during which 
decline occurs, preceded and followed by periods in which 
no perceptible decline occurs. Their procedure focuses on 
identifying the beginning and end of the period of decline for 
each patient as well as calculating the rate of decline during 
the decline period. This trilinear approach differs from the 
modeling approach we use (12) in several substantial ways. 
First, our approach makes no initial assumption regarding 
the "shape" of the decline process. Rather, it derives it 
empirically. We see no reason for the a priori assumption 
that differing aspects of disease progression can be charac-
terized by a single model. The published application of the 
trilinear model has analyzed the progression of MMSE 
scores. In this case the trilinear model would appear to 
roughly capture progression in a fashion similar to the 
function we describe here for mMMS progression. How-
ever, the trilinear approach would ignore the more subtle 
changes in scores occurring earlier and later in the disease 
and would treat the period of maximal decline as linear. In 
one analysis ( 11) they calculated that prior to the period of 
rapid decline there is a period of no perceptible decline in 
which the MMSE score is 20.7. The maximum MMSE score 
is 30, so it is likely that some decline is actually taking place 
during this period, albeit at a slower rate. Thus, we find that 
the estimated 6-month change in mMMS scores is much 
smaller when scores are close to the maximum. Further, 
since the trilinear approach assumes that progression, when 
it occurs, is constant, it would be less successful in charac-
terizing the period of rapid progression of mMMS scores, 
which is not linear. 
On a more technical level, the approach to·deriving the 
two types of models differs as well. The modeling apgroach 
we use utilizes changes in scores over consistent time inter-
vals. This represents an adaptation of standard growth curve 
models, which utilize actual scores. Standard growth curve 
models are functions of time and require knowledge of the 
absolute start of the period of progression. fn diseases such 
as AD it is difficult to accurately estimate the time of onset. 
On a mathematical basis, utilizing change scores eliminates 
the requirement for an absolute startpoint and a1lows estima-
tion of a function that characterizes change in the scores. For 
a patient to be included in the estimation process, at least two 
consecutive visits are required, because a change score over 
a fixed interval must be calculated. Beyond that require-
ment, all data from all patients are included in the analysis, 
with the assumption that observed progression in each pa-
tient represents a piece, or partial realization, of a typical 
patte111 of progression. The trilinear approach utilizes ob-
served data points, requires a minimum of 5 points for its 
application, and eliminates patients whose data do not fit a 
particular component of the model from the estimation 
process. 
A final advantage of the modeling approach we utilize is 
that it allows the incorporation of covariates. There is in-
creasing evidence that specific clinical features of AD are 
associated with differential rates of decline. The ability to 
incorporate these features into a model would bring us closer 
to the point of making accurate predictions of rate of decline 
for individual patients. Application of covariates is beyond 
the scope of the present study, but our original description of 
the modeling approach demonstrates how the model of 
mMMS progression can be refined to reflect differences in 
patients with early and late disease onset (13). 
The modeling procedure itself does not address the issue 
of the relative timing of the changes in cognition, IADL and 
BADL. In Figure 7, we have superimposed the three pro-
gression curves in a manner which we believe is representa-
tive of their relative decline. The decisions about relative 
placement of the 3 curves were guided by inspection of the 
data set at different point in disease progression. For exam-
ple, we determined the typical IADL and BADL scores for 
patients with specific mMMS scores. We include this figure 
in the Discussion section because the relative placement of 
the curves is not derived from our statistical modeling 
procedures. Inspection of the figure indicates that cognitive 
decline may begin much earlier than functional decline. 
Thus, AD might not be noticed or diagnosed until 5 or 6 
years into the progression of the mMMS scores, about the 
time when IADL problems begin. Relatively rapid decline of 
cognitive and IADL functions follows, with slowly increas-
ing BADL difficulties beginning some time afterward. Sev-
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Figure 7. Proposed model for the relative decline in cognition, instru-
mental ADL, and basic ADL in Alzheimer's disease. 
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eral recent reports suggesting that cognitive change may 
begin well before dementia is diagnosed (22,23) are consist-
ent with this proposed model. 
Our results have clear implications for both the prediction 
of disease course in AD and the planning of clinical trials. 
The fact that rates of progression vary as a function of 
current severity means that careful consideration of baseline 
severity is important when planning studies that have a 
prospective component. Further validation and development 
of this approach, particularly with the addition of relevant 
covariates, may contribute to the development of predictor 
models for individual patients. 
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